Document is current
Any future updates will be listed below
-
Authors
Migliaccio, Ilenia https://orcid.org/0000-0001-9055-4522
Paoli, Marta
Risi, Emanuela
Biagioni, Chiara https://orcid.org/0000-0002-7908-4854
Biganzoli, Laura
Benelli, Matteo https://orcid.org/0000-0003-1227-356X
Malorni, Luca https://orcid.org/0000-0002-4297-2997
- License Information
-
More Information
Article History
Received: 30 June 2021
Accepted: 11 January 2022
First Online: 18 February 2022
Competing interests
: The authors declare the following competing interests: E.R.: Personal financial interests (honoraria, consulting or advisory role): Lilly, Roche, Pfizer, Amgen; L.B.: Personal financial interests (honoraria, consulting or advisory role): AstraZeneca, Daiichi-Sankyo, Eisai, Genomic Health, Lilly, Novartis, Pfizer, Pierre Fabre. Institutional financial interests: Celgene, Genomic Health, Novartis; M.B.: Consultant honoraria: Novartis; L.M.: Speaker/consultant honoraria: Novartis, Pfizer, Lilly. Research Grant: Novartis, Pfizer. The remaining authors declare no competing interests.
